New science is the engine of progress. Airfinity is the tool to unlock the future.
Featured in more than 200 newspapers, journals and on TV networks worldwide
The world’s leading covid-19 platform
Airfinity has fast become the most globally trusted COVID-19 solution by decision makers. Access the predictive analytics and insights solution that is saving lives, today.
What the users say
Airfinity has been instrumental in our country’s COVID response.
Head of Government Vaccine Task Force
Airfinity data has allowed us to improve our analysis on the global COVID-19 response and push conversations forward with policy makers in a number of countries.
Senior Policy Director, The ONE Campaign
You are helping us make better decisions.
Commercial Lead, Bayer
Airfinity has been critical in furnishing us and the rest of the world with COVID-19 numbers.
James Fransham, Data Journalist, The Economist
The Airfinity report is a guide for world leaders to fix a more ambitious action plan. It shows we have enough vaccines either on shelves or in production even to vaccinate 70% of the global population by May next year
Gordon Brown, WHO Ambassador for Global Health Financing and former UK Prime Minister
Vaccine production data from Airfinity has been spot on and its forecasts have been extremely correct. In a fast moving pandemic, these forecasts are really important for evidence-based policy making.
Director General, IFPMA
Subscribe today to receive
One easy-to-navigate platform with tailored dashboard views
Regular intelligence briefings and bespoke deep dives
Hotline access to Airfinity’s analysts and statisticians
We collect data from the earliest sources which allows us to provide decision makers with the most up-to-date comprehensive and granular intelligence on critical new scientific developments in real-time.
By turning millions of fragmented science-related data points into a structured data set we build dynamic forecast models and simulations for trial readouts, approval likelihood, production, pricing and more to provide better decision making tools.
All information is classified and analysed by specialised experts ensuring the highest standards and quality. Our analyst team consist of some of the most talented scientists of their generation, top KOLs and industry veterans. We are fiercely independent and data driven.
How we do it
Daily compound-centric analysis
We monitor thousands of sources in all major languages to have a molecular or disease centric view and set of impact metrics. All preclinical and clinical compounds covered.
Database access to disease prevalence, production, supply & funding
Though public sources and data partnerships, we collect unstructured signals on production, supply, deals, infections, government and company level policies.
Our forecast models for trial read outs, production and immunisations are updated as new information is available. We can integrate with our clients’ own data streams to create custom predictors.
Sign up to receive a free sample of our insights
Identify alpha rich investment opportunities with deep analysis of new scientific trends, players and technologies impacting the industry’s value chain.
Governments & Healthcare Authorities
Monitor new science to inform national biosecurity strategies, funding allocations and procurement decisions across defence, health and science ministries.
International Organisations & NGOs
Make data driven funding and strategic decisions on emerging therapeutics to improve disease response and horizon scan the broader new science landscape.
Get structured predictive industry, competitor and scientific intelligence to inform key decisions across the life cycle and empower your go-to-market strategy.
Manage your infectious disease risk. Access country level forecasts of disease prevalence with an overview of treatments and vaccines. Combine our intelligence with your own data on workforce demographics and supply chains to act in time to protect employee health and avoid disruptions.
Pharma & Biotech
Get structured, predictive market and scientific intelligence to inform key decisions across the life cycle from R&D, supply through medical affairs to commercial.
Enrich academic research and analysis with access to a real time, comprehensive and structured data set covering all new scientific developments in a given therapy area.